Skip to main content

Table 4 Patient characteristics of the ICB cohort

From: Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma

CharacteristicsNumber N(%)
All patients129100
Age in years, (range)67.11, (28−92) 
Gender  
 Female5038.8
 Male7961.2
Site of melanoma metastases  
 Cutaneous metastases6248.1
 Lymph node metastases3728.7
 Lung metastases1310.1
 Brain metastases118.5
 Abdominal metastases64.7
BRAF mutation status  
BRAF wild type8465.1
BRAF mutated4232.6
 Unknown32.3
Response to anti-PD-1 blockade  
 Progressive disease (PD)5845.0
 Partial response (PR)3930.2
 Stable disease (SD)86.2
 Complete response (CR)2217.0
 Unknown21.6
Therapeutic regimen  
 Anti-PD-1 monotherapy6852.7
 Ipilimumab, anti-PD-1 monotherapy129.3
 Ipilimumab + nivolumab1713.2
 Ipilimumab, ipilimumab + nivolumab21.5
 Anti-PD-1 monotherapy, ipilimumab + nivolumab3023.3
Medical center  
 University Hospital Bonn—dermatology10480.6
 University Hospital Bonn—oncology53.9
 University Hospital Bonn—neurosurgery/-oncology43.1
 Kantonsspital St. Gallen, Spital Grabs, Spital Wil, Spital Flawil1612.4
  1. Data include age, gender, site of the melanoma metastases, BRAF mutation status, response to anti-PD-1 blockade, therapeutic regimen, and the treating medical center of N = 129 stage IV melanoma patients receiving immune checkpoint blockade